

Atrasentan

Catalog No: tcsc1372

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:

173937-91-2

Formula:

 $C_{29}H_{38}N_2O_6S$

Pathway:

GPCR/G Protein

Target:

Endothelin Receptor

Purity / Grade:

Solubility: 10 mM in DMSO

Alternative Names: ABT-627;(+)-A 127722;A-147627

Observed Molecular Weight:

542.69

Product Description

Copyright 2021 Taiclone Biotech Corp.




Atrasentan is an **endothelin receptor** antagonist with IC_{50} of 0.0551 nM for ET_A .

IC50 & Target: IC50: 0.055 nM (ET_{A})

In Vitro: Atrasentan (ABT-627, 0-50 μ M) significantly inhibits LNCaP and C4-2b prostate cancer cell growth. ABT-627 in conbination with Taxotere elicits a significantly greater loss of viable prostate cancer cells relative to either agent alone and shows greater degree of down-regulation of the NF- κ B DNA binding activity^[2]. Atrasentan profoundly induces several CYPs and drug transporters (e.g. 12-fold induction of CYP3A4 at 50 μ M). It is a moderate P-gp inhibitor (IC₅₀ in P388/dx cells=15.1±1.6 μ M) and a weak BCRP inhibitor (IC₅₀ in MDCKII-BCRP cells=59.8±11 μ M)^[3].

In Vivo: Atrasentan (3 mg/kg, p.o.) inhibits the pressor response induced by big endothelin-1 (1 nmol/kg) in pithed rats^[1]. Aatrasentan (ABT-627, 10 mg/kg, i.p.) as well as Taxotere alone inhibited the C4-2b tumor growth within the bone environment to some extent in the SCID-hu model^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.